ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > For those that Sold at 0.26 CAD Today

<< Previous

Bullboard Posts

Next >>

Comment by garygpon Aug 10, 2021 2:08pm

130 Views

Post# 33679043

RE:RE:RE:RE:For those that Sold at 0.26 CAD Today

With the modest run-up in the stock over the past month on both volume and price, it appears to me they are putting lipstick on the pig, getting it ready for another financing.

Couple this with Elliot not having left yet, it seems like the perfect storm. Afterall, he is the leader and Father of dilution and shareholder inequity.

Oh how I hope I am wrong. Hope the Boston group (FEG) sees through the stupidity and puts a lid on it before it grows.

G.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?